MASI:NSD-Masimo Corporation (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 114.31

Change

-0.70 (-0.61)%

Market Cap

USD 6.03B

Volume

0.48M

Analyst Target

USD 251.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+0.52 (+0.75%)

USD 27.85B
PODD Insulet Corporation

+0.57 (+0.24%)

USD 16.40B
BRKR Bruker Corporation

+1.77 (+2.72%)

USD 9.94B
TMDX TransMedics Group Inc

-0.12 (-0.08%)

USD 5.04B
PRCT Procept Biorobotics Corp

+3.16 (+3.96%)

USD 4.00B
AXNX Axonics Modulation Technologie..

-0.18 (-0.26%)

USD 3.52B
QDEL Quidel Corporation

-0.12 (-0.26%)

USD 3.06B
TNDM Tandem Diabetes Care Inc

-0.42 (-0.98%)

USD 2.88B
LIVN LivaNova PLC

+0.07 (+0.14%)

USD 2.64B
NARI Inari Medical Inc

+0.28 (+0.63%)

USD 2.61B

ETFs Containing MASI

MEDI Harbor Health Care ETF 4.70 % 0.00 %

+0.08 (+0.34%)

USD 0.01B
EDOC:AU BetaShares Digital Health.. 3.91 % 0.00 %

+0.03 (+0.34%)

N/A
EQWM 0.00 % 0.25 %

N/A

N/A
PXMG 0.00 % 0.39 %

N/A

N/A
YXM.A:CA 0.00 % 1.49 %

N/A

N/A
YXM.D:CA 0.00 % 1.53 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.47% 68% D+ 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.47% 68% D+ 44% F
Trailing 12 Months  
Capital Gain 14.46% 73% C 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.46% 73% C 62% D
Trailing 5 Years  
Capital Gain -24.79% 63% D 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.79% 63% D 33% F
Average Annual (5 Year Horizon)  
Capital Gain -4.90% 40% F 32% F
Dividend Return -4.90% 40% F 30% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.30% 82% B 53% F
Risk Adjusted Return -13.87% 39% F 32% F
Market Capitalization 6.03B 97% N/A 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.